Monday, July 18, 2022
Filament Health (FLHLF)
Patient Dosing Has Begun in Phase I Psilocin Trial, Seventh Patent Issued, and New Funds Raised
Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Recent Progress Has Been Made In Several Areas. Filament Health has announced the dosing of the first patient in the Phase 1 trial testing orally administered psilocybin against its two formulations of psilocin. This trial will compare psilocybin with two proprietary formulations of psilocin, its active metabolite. The company has also announced the issuance of its seventh patent and raised $2.5 million through a Private Placement.
The trial is being conducted at the University of San Francisco’s Translational Psychedelic Research Program (TrPR), a collaboration of academic scientists and clinicians from several medical specialties that are exploring the use of psychedelic compounds as therapeutics. The clinical trial consists of three dosing arms, with patients receiving the orally administered formulation of psilocybin, PEX010, the orally administered formulation of psilocin, PEX020, or the sublingual formulation, PEX030. The study will compare the physiological and psychological effects of the three formulations, dosing consistency, and the related side-effects….
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
